IGIV-C 10% ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
65原発性免疫不全症候群2

65. 原発性免疫不全症候群


臨床試験数 : 500 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02604810
(ClinicalTrials.gov)
January 20166/11/2015Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyAn Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary ImmunodeficiencyPrimary ImmunodeficiencyBiological: IGIV-C 10%;Biological: IGSC 20%Grifols Therapeutics LLCNULLCompleted2 Years75 YearsAll53Phase 3United States;Canada
2NCT00220766
(ClinicalTrials.gov)
August 200213/9/2005Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsIGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient PatientsImmunologic Deficiency Syndrome;Agammaglobulinemia;Severe Combined Immunodeficiency;Wiskott-Aldrich Syndrome;Common Variable ImmunodeficiencyDrug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Drug: Dextrose, 5% in WaterGrifols Therapeutics Inc.NULLCompleted18 Years75 YearsBoth100Phase 3United States;Canada